[go: up one dir, main page]

IL212214A0 - Use of lipid conjugates in the treatment of disease - Google Patents

Use of lipid conjugates in the treatment of disease

Info

Publication number
IL212214A0
IL212214A0 IL212214A IL21221411A IL212214A0 IL 212214 A0 IL212214 A0 IL 212214A0 IL 212214 A IL212214 A IL 212214A IL 21221411 A IL21221411 A IL 21221411A IL 212214 A0 IL212214 A0 IL 212214A0
Authority
IL
Israel
Prior art keywords
disease
treatment
lipid conjugates
conjugates
lipid
Prior art date
Application number
IL212214A
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/989,607 external-priority patent/US7772196B2/en
Priority claimed from US10/989,606 external-priority patent/US7811999B2/en
Priority claimed from PCT/US2005/006591 external-priority patent/WO2005084307A2/en
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL212214A priority Critical patent/IL212214A0/en
Publication of IL212214A0 publication Critical patent/IL212214A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL212214A 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease IL212214A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL212214A IL212214A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/989,607 US7772196B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
US10/989,606 US7811999B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
PCT/US2005/006591 WO2005084307A2 (en) 2004-03-02 2005-03-02 Use of lipid conjugates in the treatment of disease
PCT/IL2005/001225 WO2006054304A2 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease
IL212214A IL212214A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease

Publications (1)

Publication Number Publication Date
IL212214A0 true IL212214A0 (en) 2011-06-30

Family

ID=39619055

Family Applications (3)

Application Number Title Priority Date Filing Date
IL183227A IL183227A0 (en) 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease
IL212214A IL212214A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease
IL212215A IL212215A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL183227A IL183227A0 (en) 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL212215A IL212215A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease

Country Status (10)

Country Link
EP (1) EP1819345A4 (en)
JP (2) JP2008520650A (en)
CN (1) CN101175499B (en)
AU (1) AU2005305456B2 (en)
BR (1) BRPI0516810A (en)
CA (1) CA2587883A1 (en)
EA (1) EA012138B1 (en)
IL (3) IL183227A0 (en)
MX (1) MX2007005975A (en)
WO (1) WO2006054304A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
CA2761590C (en) * 2009-05-11 2018-08-28 Morria Biopharmaceuticals Lipid-polymer conjugates, their preparation and uses thereof
WO2014070769A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
JPWO2015005459A1 (en) * 2013-07-10 2017-03-02 生化学工業株式会社 Pharmaceutical composition for respiratory administration
CA3029005A1 (en) * 2016-06-27 2018-01-04 Ohio State Innovation Foundation Liponucleotide-based therapy for ards
KR20230117644A (en) 2016-11-17 2023-08-08 레노비온, 아이엔씨. Treatment of respiratory tract diseases and infections with glutathione compositions
AU2018367674B2 (en) 2017-11-17 2025-02-27 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
EP4460319A2 (en) 2022-01-04 2024-11-13 Renovion, Inc. Aqueous solution comprising a glutathione salt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
JPH0232013A (en) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk Nasal drop
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
ES2044781B1 (en) * 1992-04-14 1994-10-01 Menarini Lab PROCEDURE FOR THE PREPARATION OF NEW AMIDES WITH PHOSPHOLIPASE A2 INHIBITING ACTION
JP3714683B2 (en) * 1992-07-30 2005-11-09 生化学工業株式会社 Anti-rheumatic agent
FI971494A7 (en) * 1994-10-14 1997-04-10 Zeneus Pharma Ltd Enterlipid liposomes and their therapeutic use
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JPH11147901A (en) * 1997-11-19 1999-06-02 Maruho Co Ltd Kallikrein-kinin system inhibitor
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
JP4782966B2 (en) * 2000-01-10 2011-09-28 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド Use of lipid conjugates in the treatment of disease
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases

Also Published As

Publication number Publication date
BRPI0516810A (en) 2008-09-23
EP1819345A4 (en) 2012-04-18
JP2012001559A (en) 2012-01-05
MX2007005975A (en) 2007-10-08
EP1819345A2 (en) 2007-08-22
AU2005305456A1 (en) 2006-05-26
EA012138B1 (en) 2009-08-28
CN101175499B (en) 2010-12-22
CA2587883A1 (en) 2006-05-26
AU2005305456B2 (en) 2011-05-19
IL212215A0 (en) 2011-06-30
CN101175499A (en) 2008-05-07
IL183227A0 (en) 2007-08-19
EA200701077A1 (en) 2008-04-28
JP2008520650A (en) 2008-06-19
WO2006054304A2 (en) 2006-05-26
WO2006054304A3 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
IL180078A (en) 9-cis-retinal derivative for use in the treatment of 11-cis -retinal deficiency
IL184884A0 (en) Extending time or disease progression or survival in cancer patients
GB0410725D0 (en) Pyrrolobenzodiazepine therapeutic agents
IL150628A0 (en) Use of lipid conjugates in the treatment of disease
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
EP1957462A4 (en) Novel 2-amino-heterocycles udeful in the treatment of abeta-related pathologies
EP2094281A4 (en) Use of lipid conjugates in the treatment of diseases or disorders of the eye
PL1912650T3 (en) Use of flibanserin in the treatment of obesity
SI1885380T1 (en) Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
EP1874800A4 (en) Diagnostic and therapeutic agents
IL181300A0 (en) Photosensitizer formulations and uses thereof
PT2340872T (en) New pharmaceutical formulations useful in the treatment of insomnia
EP1757282A4 (en) The use of kauranes compounds in the manufacture of medicament
IL185575A0 (en) Benzoxazocines and their therapeutic use
EP1951914A4 (en) Diagnostic and therapeutic methods and agents
IL229981A0 (en) Use of lipid conjugates in the treatment of disease
IL229982A0 (en) Use of lipid conjugates in the treatment of disease
IL229980A0 (en) Use of lipid conjugates in the treatment of disease
GB0501655D0 (en) Therapeutic use
HK1102108A (en) Use of lipid conjugates in the treatment of diseases
GB0402598D0 (en) Improvements in or relating to patient support
EP1956001A4 (en) Pharmaceutical for use in the treatment of ureterolithiasis
HK1111892A (en) Use of pyrazolyl-pyrimidine derivatives in the treatment of pain